AstraZeneca/Merck's Lynparza gains expanded prostate cancer indication
CreVis2         
The US FDA has expanded the prostate cancer indication for AstraZeneca (NASDAQ:AZN)/Merck's (NYSE:MRK) Lynparza (olaparib) as aÂ  first-line treatment for adultsÂ withÂ BRCA-mutated metastatic castration-resistant prostate cancer.

The new indicationÂ is in combination with abiraterone and prednisone or prednisolone.
The companies wanted the expanded indication to include the Lynparza combo in those without the BRCA mutation, but an FDA advisory committee in April declined to endorse this.

More on Lynparza

AstraZeneca's Imfinzi, Lynparza cuts risk of uterus cancer progression in phase 3 trial
AstraZeneca Imfinzi, Lynparza combo improves progression-free survival in ovarian cancer trial